News

Introducing Dr. Madeleine Strach, the 2022 recipient of the ANZSA Clinical Research Fellowship which has been co-funded by The Kids Cancer Project and Rainbows for Kate.

Fernando Guimaraes is the 2021 ANZSA research grant recipient and a group leader at The University of Queensland Diamantina Institute. Australia and New Zealand Sarcoma Association spoke with Dr Guimaraes to discover how his research into harnessing our own immune system to fight sarcoma is progressing.   

ANZSA is excited to announce the release of their first series of the new sarcoma guidelines. With these new guidelines, ANZSA aims to improve the care of patients with sarcoma from the initial diagnosis through to staging, treatment and follow up.

Research conducted by ANZSA featured in the rEECUR plenary presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past June.

We're delighted to introduce a range of ANZSA merchandise available for purchase. You can buy our merchandise for fundraising purposes or as a gift!

ANZSA is proud to announce that one of two Sarcoma Research Grants has been awarded to Dr Fernando Guimaraes from The University of Queensland Diamantina Institute. Read more about Dr Guimaraes' research project.

ANZSA is proud to announce that one of two Sarcoma Research Grant was awarded to Dr Vijesh Vaghjiani from the Hudson Institute of Medical Research. Read more about Dr Vaghjiani's research project.

ANZSA Director, A/Prof David Gyorki, together with his team successfully received a grant worth almost AUD$1 million from an MRFF Grant for STRASS 2 trial. Read more about it.

The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin) for Australian patients. Read more...

This is the results summary of the EWING 2008 - a joint study of the European and North American Ewing sarcoma study groups.

Great news for all Australian patients diagnosed with rhabdomyosarcoma (RMS). The Chris O’Brien Lifehouse (NSW) is the first sarcoma specialist centre in Australia to start patient recruitment for the all-important clinical trial – FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma.

Read our tribute to our great friend, mentor and colleague, Professor Martin Tattersall AO.